Eyantra Ventures Q1FY27 Results: Net loss widens to ₹374.95 lakh

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Consolidated net loss widened to ₹374.95 lakh in Q1FY27 from ₹342.62 lakh in Q1FY26
  • Revenue from operations fell 2% YoY to ₹1,917.42 lakh, driven by sharp drop in hospital services
  • Employee benefit expenses surged to ₹599.69 lakh, up from ₹392.38 lakh in the prior quarter
  • Non-controlling interest accounted for nearly half of the total net loss at ₹184.71 lakh
  • Board approved closure of UAE subsidiary and merger of Prismberry Technologies
powered bylight_fuzz_icon
49382946

*this image is generated using AI for illustrative purposes only.

The Board of Directors of Eyantra Ventures approved the unaudited consolidated financial results for the quarter ended June 30, 2026, on August 27, 2026. The company reported a net loss attributable to shareholders of ₹190.24 lakh, widening from a loss of ₹172.65 lakh in the same period last year.

Total revenue from operations declined 2% year-on-year to ₹1,917.42 lakh in Q1FY27, compared to ₹1,956.41 lakh in Q1FY26. This marks a significant drop from the previous quarter’s audited revenue of ₹2,528.72 lakh.

Financial Performance

Total expenses for the quarter stood at ₹2,288.24 lakh, resulting in a pre-tax loss of ₹357.50 lakh. In contrast, the company posted a pre-tax profit of ₹688.99 lakh in Q4FY26 and a loss of ₹328.83 lakh in Q1FY26.

Metric Q1FY27 (Unaudited) Q4FY26 (Audited) Q1FY26 (Unaudited)
Revenue from operations ₹1,917.42 lakh ₹2,528.72 lakh ₹1,956.41 lakh
Total expenses ₹2,288.24 lakh ₹1,862.80 lakh ₹2,295.79 lakh
Profit/(Loss) before tax (₹357.50) lakh ₹688.99 lakh (₹328.83) lakh
Net profit/(loss) (₹374.95) lakh ₹677.97 lakh (₹342.62) lakh

Employee benefit expenses rose significantly to ₹599.69 lakh in Q1FY27, up from ₹392.38 lakh in the preceding quarter. Purchase of stock-in-trade also increased to ₹952.31 lakh from ₹909.03 lakh.

Segment Analysis

Revenue breakdown reveals a sharp contraction in hospital services, which contributed only ₹153.99 lakh in Q1FY27, down from ₹1,038.86 lakh in Q4FY26. Sale of merchandise revenue grew 19% sequentially to ₹1,235.73 lakh. IT services revenue also expanded to ₹526.35 lakh from ₹386.17 lakh.

Domestic revenue accounted for ₹1,782.45 lakh, while overseas revenue was ₹134.97 lakh. The company noted that segment-wise operating costs are not allocated by the Chief Operating Decision Maker, making segment profitability unascertainable.

What the Numbers Show

A notable divergence exists between the group’s total comprehensive income and the portion attributable to shareholders. While the total net loss for the period was ₹374.95 lakh, the non-controlling interest absorbed ₹184.71 lakh of this loss. This indicates that the majority of the operational drag originated from subsidiaries rather than the holding company’s standalone operations.

Corporate Developments

The board decided to close eYantra Ventures FZE, UAE, a non-functioning wholly owned subsidiary, during its meeting on July 2, 2026. Additionally, the National Company Law Tribunal, Hyderabad, approved the merger of wholly owned subsidiary Prismberry Technologies Private Limited into the parent company, with an appointed date of April 1, 2026.

PRSV & Co. LLP served as the independent auditor for the limited review of the quarterly results.

Historical Stock Returns for Eyantra Ventures

1 Day5 Days1 Month6 Months1 Year5 Years
+0.08%-11.98%-21.69%-46.85%-43.46%0.0%

What specific operational or market factors caused the sharp 85% sequential decline in hospital services revenue, and is this trend expected to persist in Q2FY27?

How will the recent merger of Prismberry Technologies and the closure of the UAE subsidiary impact Eyantra Ventures' consolidated cost structure and administrative overheads in the coming quarters?

Given that non-controlling interests absorbed nearly half of the net loss, what are the financial health prospects of the key subsidiaries, and are there plans to restructure these joint ventures?

Eyantra Ventures publishes NCLT 3A ad for Prismberry scheme

scanx
Reviewed by
Naman SScanX News Team
Key Highlights

Eyantra Ventures Limited published the Form NCLT 3A advertisement for its scheme of arrangement with Prismberry Technologies Private Limited. The petition, filed under Sections 230 to 232 of the Companies Act, 2013, was admitted by the NCLT Hyderabad Bench II on August 14, 2026. The hearing is scheduled for October 9, 2026.

powered bylight_fuzz_icon
48684779

*this image is generated using AI for illustrative purposes only.

Eyantra Ventures Limited has published the newspaper advertisement in Form No. NCLT 3A detailing its petition for a scheme of arrangement with Prismberry Technologies Private Limited. The move follows an order dated August 14, 2026, from the National Company Law Tribunal (NCLT), Hyderabad Bench II.

The scheme involves the amalgamation of Prismberry Technologies, the transferor company, with Eyantra Ventures, the transferee company. The joint petition was presented under Sections 230 to 232 of the Companies Act, 2013, on July 28, 2026. The advertisement was published on August 19, 2026, in Financial Express and Prajasakti.

Key Dates and Details

Event Date
Petition Presented July 28, 2026
Petition Admitted August 14, 2026
Advertisement Published August 19, 2026
Hearing Fixed October 9, 2026

The petition is now fixed for hearing before the NCLT, Hyderabad Bench II, on October 9, 2026. Any person desirous of supporting or opposing the petition must send notice to the tribunal and the petitioners' registered office at least two days before the hearing date.

Prismberry Technologies is represented by Whole-time Director Manoj Kumar Yadav, while Eyantra Ventures is represented by Chairperson and Managing Director Vinita Raj Narayanam.

Historical Stock Returns for Eyantra Ventures

1 Day5 Days1 Month6 Months1 Year5 Years
+0.08%-11.98%-21.69%-46.85%-43.46%0.0%

What strategic synergies or market expansion goals are driving Eyantra Ventures to acquire Prismberry Technologies?

How might the amalgamation impact Eyantra Ventures' financial metrics, such as revenue growth and debt-to-equity ratios, in the post-merger period?

Are there any anticipated regulatory hurdles or shareholder dissent that could delay the NCLT approval scheduled for October 9, 2026?

More News on Eyantra Ventures

1 Year Returns:-43.46%